Suppr超能文献

[抑肽酶的过敏风险]

[Allergic risk of aprotinin].

作者信息

Laxenaire M C, Dewachter P, Pecquet C

机构信息

Département d'anesthésie-réanimation, hôpital central, Nancy.

出版信息

Ann Fr Anesth Reanim. 2000 Feb;19(2):96-104. doi: 10.1016/s0750-7658(00)00114-3.

Abstract

OBJECTIVE

To analyse the risk of anaphylactic reaction with the administration of aprotinin, either by i.v. route or as a biological sealant application and to propose updated guidelines in accordance with current data of the literature.

DATA SOURCES

Search in the Medline data base of articles in French, English and German, published since 1960, using following key words: aprotinin, allergy, anaphylaxis.

STUDY SELECTION

All categories of articles on this topic have been selected.

DATA EXTRACTION

Articles have been analysed for history, incidence and mechanisms of anaphylactic reactions, symptomatology, factors of risk, diagnosis and precautions of use.

DATA SYNTHESIS

Aprotinin is widely used for decreasing preoperative bleeding, especially in cardiac and orthopaedic surgery. This heterologue protein can cause anaphylactic reactions in 0.5 to 5.8% of patients, depending of the inclusion criteria. They are mediated by IgG and IgE antibodies. Aprotinin has also a direct, non specific, histaminoliberation effect. The clinical presentation includes various degrees of severity, up to cardiac arrest. Documented factors of risk are a previous parotinin administration, 15 days to 6 months before, and intolerance to beef meat, white of egg, cheese and milk. The immediate biological diagnosis is obtained on assessing the degranulation of basophiles (histamine) and mastocytes (tryptase), as well as the concentration of anti-aprotinin antibodies (RAST IgE), with a test of inhibition. The secondary assessment, six weeks later, includes prick-tests and intradermoreactions if the former are negative. The mean precaution consists to search factors of risk at preanaesthetic assessment. The predictive value of systematic prick-tests has not yet been validated. Anti H1 and anti H2 premedication is inefficient. A test dose can trigger a severe reaction.

CONCLUSION

Considering a significant anaphylactic risk, aprotinin administration becomes only licit after a careful evaluation of the benefit-risk ratio.

摘要

目的

分析静脉注射抑肽酶或作为生物密封剂使用时发生过敏反应的风险,并根据当前文献数据提出更新指南。

数据来源

检索自1960年以来发表的法语、英语和德语文章的Medline数据库,使用以下关键词:抑肽酶、过敏、过敏反应。

研究选择

选取了关于该主题的所有类别文章。

数据提取

分析文章中过敏反应的病史、发生率和机制、症状、风险因素、诊断及使用注意事项。

数据综合

抑肽酶广泛用于减少术前出血,尤其是在心脏和骨科手术中。这种异体蛋白可导致0.5%至5.8%的患者发生过敏反应,具体比例取决于纳入标准。过敏反应由IgG和IgE抗体介导。抑肽酶还具有直接的、非特异性的组胺释放作用。临床表现包括不同程度的严重程度,直至心脏骤停。已记录的风险因素包括先前在15天至6个月前使用过抑肽酶,以及对牛肉、蛋清、奶酪和牛奶不耐受。通过评估嗜碱性粒细胞(组胺)和肥大细胞(类胰蛋白酶)的脱颗粒以及抗抑肽酶抗体(RAST IgE)的浓度,并进行抑制试验,可获得即时生物学诊断。六周后的二次评估包括针刺试验和皮内反应(如果前者为阴性)。主要的预防措施是在麻醉前评估时寻找风险因素。系统性针刺试验的预测价值尚未得到验证。使用H1和H2拮抗剂进行术前用药无效。试验剂量可能引发严重反应。

结论

考虑到存在显著的过敏风险,在仔细评估利弊比后,抑肽酶的使用才合法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验